AGI provides comprehensive GLP-compliant and exploratory toxicology studies to characterize the safety, tolerability, and biological impact of therapeutic candidates. Our capabilities cover acute, sub-chronic, and chronic toxicology, incorporating dose-range finding, repeat-dose studies, and safety pharmacology across major therapeutic modalities. By integrating advanced endpoints, including clinical pathology, histopathology, biomarker profiling, telemetry, and imaging, we generate high-resolution datasets that provide a detailed view of systemic and organ-specific effects under clinically relevant conditions. Each study is tailored to sponsor objectives, whether supporting early-stage exploratory assessments or generating definitive safety packages for regulatory submissions.

 

Our multidisciplinary teams of toxicologists, veterinarians, and regulatory specialists ensure that all protocols are executed with precision, reproducibility, and strict adherence to international GLP standards. Beyond technical rigor, we emphasize translational value, designing studies that not only document adverse event profiles but also inform dose selection, risk mitigation, and human clinical trial design. Through this combination of scientific expertise, regulatory alignment, and operational excellence, Alpha Genesis helps sponsors de-risk development pipelines, accelerate therapeutic progress, and achieve reliable outcomes that support FDA, EMA, and global approval pathways.